David Gentien
Overview
Explore the profile of David Gentien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
3051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filser M, Torrejon J, Merchadou K, Dufour C, Girard E, Bourneix C, et al.
Neuro Oncol
. 2024 Dec;
PMID: 39731757
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB)....
2.
Michel M, Heidary M, Mechri A, Da Silva K, Gorse M, Dixon V, et al.
Clin Cancer Res
. 2024 Dec;
PMID: 39620930
Purpose: The detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of...
3.
Geay J, Margaron Y, Gentien D, Reyal F, Puisieux A, Blanchoin L, et al.
Biol Cell
. 2024 Jun;
116(7):e2400048.
PMID: 38850178
Background Information: The control of epithelial cell polarity is key to their function. Its dysregulation is a major cause of tissue transformation. In polarized epithelial cells,the centrosome is off-centred toward...
4.
Nemati F, De Koning L, Gentien D, Assayag F, Henry E, Ait Rais K, et al.
Curr Oncol
. 2023 Oct;
30(10):9090-9103.
PMID: 37887557
Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor,...
5.
Gentien D, Saberi-Ansari E, Servant N, Jolly A, De La Grange P, Nemati F, et al.
Cell Rep
. 2023 Sep;
42(9):113132.
PMID: 37708024
Uveal melanoma (UM) is a rare cancer resulting from the transformation of melanocytes in the uveal tract. Integrative analysis has identified four molecular and clinical subsets of UM. To improve...
6.
Serror K, Ferrero L, Boismal F, Sintes M, Thery M, Vianay B, et al.
Exp Dermatol
. 2023 May;
32(7):1096-1107.
PMID: 37148203
Keloid scars are hypertrophic and proliferating pathological scars extending beyond the initial lesion and without tendency to regression. Usually, keloids are considered and treated as a single entity but clinical...
7.
Neyret-Kahn H, Fontugne J, Meng X, Groeneveld C, Cabel L, Ye T, et al.
Oncogene
. 2023 Mar;
42(19):1524-1542.
PMID: 36944729
Muscle-invasive bladder cancer (BLCA) is an aggressive disease. Consensus BLCA transcriptomic subtypes have been proposed, with two major Luminal and Basal subgroups, presenting distinct molecular and clinical characteristics. However, how...
8.
El-Botty R, Vacher S, Mainguene J, Briaux A, Ibadioune S, Dahmani A, et al.
Mol Oncol
. 2023 Feb;
17(10):2017-2028.
PMID: 36852691
Triple negative breast cancers (TNBCs) represent 15-20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines...
9.
Fontugne J, Wong J, Cabel L, Neyret-Kahn H, Karboul N, Maille P, et al.
J Pathol
. 2023 Jan;
259(4):455-467.
PMID: 36695554
The aggressive basal/squamous (Ba/Sq) bladder cancer (BLCA) subtype is often diagnosed at the muscle-invasive stage and can progress to the sarcomatoid variant. Identification of molecular changes occurring during progression from...
10.
Silina L, Dufour F, Rapinat A, Reyes C, Gentien D, Maksut F, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955805
Bladder cancer is a common cancer; it is the tenth most common cancer in the world. Around one fourth of all diagnosed patients have muscle-invasive bladder cancer (MIBC), characterized by...